Possible scenario
Rapid Pediatric Adoption
38% Chance
WHO backing accelerates clinical acceptance of GLP-1 weight-loss injections for children age 10 and older. Pediatric endocrinology groups and obesity specialists incorporate the recommendation into treatment protocols, expanding the perceived market for Novo Nordisk and Eli Lilly.
Secondary impacts
- Healthcare +1.0%
- Consumer Non-Cyclicals -0.3%
Tickers
- LLY+3.5%
- WW+1.4%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.